Company news

Summit Therapeutics Inc. news in 2024

Summit Therapeutics Inc.'s news releases, calls and decks from 2024, newest first.

View company

Summit Therapeutics Reports Operational Progress and Financial Results for the Third Quarter and Nine Months Ended September 30, 2024

October 29, 2024

Summit Therapeutics to Host Third Quarter 2024 Financial Results & Operational Progress Call on October 30, 2024

October 22, 2024

Summit Therapeutics Announces Completion of Enrollment in Its Phase III HARMONi Trial in 2L+ EGFRm NSCLC

October 2, 2024

Promising Anti-Tumor Activity and Safety of Ivonescimab in Combination Therapies in CRC, TNBC, and HNSCC Featured at ESMO 2024

September 15, 2024

Summit Therapeutics Raises $235 Million

September 11, 2024

Ivonescimab Monotherapy Reduced the Risk of Disease Progression or Death by 49% Compared to Pembrolizumab Monotherapy in First-Line Treatment of Patients with PD-L1 Positive Advanced NSCLC in China

September 7, 2024

HARMONi-2, Featuring Ivonescimab Monotherapy vs. Pembrolizumab Monotherapy, to be Showcased in Presidential Symposium at WCLC 2024

August 11, 2024

Two Ivonescimab (PD-1/VEGF) Results including Phase 3 Monotherapy versus Pembrolizumab Monotherapy in First-Line Treatment for PD-L1 Positive NSCLC to Be Presented at WCLC 2024

August 10, 2024

Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter and Six Months Ended June 30, 2024

August 5, 2024

Summit Therapeutics to Host Second Quarter 2024 Financial Results & Operational Progress Call on August 6, 2024

July 28, 2024

Summit Therapeutics and MD Anderson Announce Strategic Collaboration to Accelerate Development of Ivonescimab

July 24, 2024

Summit Therapeutics Appoints Jeff Huber, Transformational Google and GRAIL Executive, to its Board of Directors

June 26, 2024

Summit Raises $200 Million; Also Expands License Territories for Ivonescimab

June 2, 2024

Ivonescimab Manuscript for HARMONi-A Clinical Trial Results Published in JAMA

May 31, 2024

Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for 2L+ EGFRm NSCLC based on HARMONi-A Clinical Trial: Positive Trend Observed in Overall Survival towards Ivonescimab Plus Chemotherapy

May 30, 2024

Ivonescimab Monotherapy Decisively Beats Pembrolizumab Monotherapy Head-to-Head, Achieves Statistically Significant Superiority in PFS in First-Line Treatment of Patients with PD-L1 Positive NSCLC in China

May 29, 2024

Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2024

April 30, 2024

Summit Therapeutics to Host First Quarter 2024 Financial Results & Operational Progress Call on May 1, 2024

April 23, 2024

Summit Therapeutics Appoints Dr. Mostafa Ronaghi, Renowned Executive and Genomicist, to its Board of Directors

April 10, 2024

Summit Therapeutics to Present at the Stifel 2024 Targeted Oncology Forum

April 9, 2024

Intracranial Anti-Tumor Activity and Safety of Ivonescimab in NSCLC Patients with Brain Metastases to be Featured at ELCC 2024

March 13, 2024

Summit Therapeutics to Present at the Barclays 26th Annual Global Healthcare Conference

March 4, 2024

Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2023

February 19, 2024

Summit Therapeutics to Host Fourth Quarter & Full Year 2023 Financial Results & Operational Progress Call on February 20, 2024

February 13, 2024

Summit Therapeutics to Present at Oppenheimer’s 34th Annual Healthcare Life Sciences Conference

February 6, 2024

Summit Therapeutics Announces Updated Phase II Data for Ivonescimab at 42nd Annual J.P. Morgan Healthcare Conference

January 7, 2024

Summit Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

January 2, 2024

Calls in 2024

Decks in 2024